Drug Profile

Research programme: viral vaccines - DMK Pharmaceuticals

Latest Information Update: 13 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Adamis Pharmaceuticals Corporation
Developer DMK Pharmaceuticals
Class Cell therapies; Influenza virus vaccines; Viral hepatitis vaccines; Viral vaccines
Mechanism of Action Cell replacements; Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

07 Sep 2023 Adamis Pharmaceuticals Corporation is now called DMK Pharmaceuticals
31 Jul 2013 Suspended - Preclinical for Influenza virus infections in USA (Parenteral)
31 Jul 2009 Preclinical trials in Influenza virus infections in USA (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com